Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033784 · ClinicalTrials.gov registry record · Phase 2
Autism Oxytocin Brain Project
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03033784 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 51 participants.
The verdict
NCT03033784, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The main goal of the study is to look at the effects of intranasal oxytocin on the brain in Autism Spectrum Disorder (ASD). Oxytocin is a hormone that exists naturally in the body and the brain, affecting a wide range of social behaviors and emotions. The investigators will study the effects of different treatments (3 doses of oxytocin and one dose of placebo) on brain functional connectivity at rest in patients with ASD, using functional magnetic resonance imaging (fMRI). Investigators also seek to study how the effects of oxytocin treatment can be affected by genetic, immune and environmental factors.
Interventions
- DRUG Placebo
- DRUG 8 International Units (IU) of Oxytocin
- DRUG 24IU of Oxytocin
- DRUG 48IU of Oxytocin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-05-10 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033784
The ClinicalTrials.gov registry entry for NCT03033784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03033784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03033784 about?
NCT03033784 is a clinical study titled "Autism Oxytocin Brain Project". The main goal of the study is to look at the effects of intranasal oxytocin on the brain in Autism Spectrum Disorder (ASD). Oxytocin is a hormone that exists naturally in the body and the brain, affecting a wide range of social behaviors and emotions. The investigators will study the effects of diff...
What is the current status of trial NCT03033784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-05-10. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT03033784?
The interventions under investigation include: Placebo (DRUG), 8 International Units (IU) of Oxytocin (DRUG), 24IU of Oxytocin (DRUG), 48IU of Oxytocin (DRUG).
Who is sponsoring clinical trial NCT03033784?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.